Shares of Metagenomi, Inc. (NASDAQ:MGX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $15.50.
Several analysts recently weighed in on MGX shares. Chardan Capital reiterated a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a report on Thursday, September 5th. BMO Capital Markets cut their target price on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday, August 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Metagenomi in a research note on Tuesday.
Read Our Latest Research Report on MGX
Hedge Funds Weigh In On Metagenomi
Metagenomi Price Performance
NASDAQ MGX opened at $1.97 on Wednesday. Metagenomi has a 1 year low of $1.85 and a 1 year high of $12.74. The business’s 50-day moving average is $2.65 and its 200 day moving average is $4.89.
Metagenomi (NASDAQ:MGX – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.30. The business had revenue of $20.01 million during the quarter, compared to analysts’ expectations of $14.80 million. As a group, research analysts predict that Metagenomi will post -3.04 EPS for the current fiscal year.
Metagenomi Company Profile
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Featured Articles
- Five stocks we like better than Metagenomi
- 5 discounted opportunities for dividend growth investors
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- 3 Stocks to Consider Buying in October
- AMD Gains Momentum With AI: Can It Beat Expectations?
- How to Read Stock Charts for Beginners
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.